TRDA vs. CL

Last updated Jun 4, 2026

TRDA (Entrada Therapeutics, Inc.) and CL (Colgate-Palmolive Company) are both stocks. TRDA operates in Biotechnology (Healthcare), while CL operates in Household & Personal Products (Consumer Defensive). Over the past 3 years, TRDA returned -18.62%/yr vs 6.21%/yr for CL. At a 0.01 correlation, their price movements are largely independent.

Performance

TRDA vs. CL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Entrada Therapeutics, Inc. (TRDA) and Colgate-Palmolive Company (CL). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TRDA achieves a -35.99% return, which is significantly lower than CL's 8.73% return.

TRDA

• 1D: -0.90%
• 1M: -58.33%
• YTD: -35.99%
• 6M: -34.66%
• 1Y: -20.15%
• 3Y*: -18.62%
• 5Y*: —
• 10Y*: —

CL

• 1D: -3.85%
• 1M: -0.59%
• YTD: 8.73%
• 6M: 9.87%
• 1Y: -3.98%
• 3Y*: 6.21%
• 5Y*: 2.62%
• 10Y*: 4.14%

*Multi-year figures are annualized to reflect compound growth (CAGR)

TRDA vs. CL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
TRDA Entrada Therapeutics, Inc.	-35.99%	-40.54%	14.58%	11.61%	-21.03%	-28.52%
CL Colgate-Palmolive Company	8.73%	-10.98%	16.57%	3.78%	-5.44%	12.01%

Correlation

The correlation between TRDA and CL is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.02
Correlation (All Time) Calculated using the full available price history since Nov 1, 2021	0.01

Fundamentals

Market Cap TRDA : $275.28M CL : $68.33B
EPS TRDA : -$4.00 CL : $2.58
PS Ratio TRDA : 47.59 CL : 3.30
PB Ratio TRDA : 1.02 CL : 471.23
Total Revenue (TTM) TRDA : $5.74M CL : $20.80B
Gross Profit (TTM) TRDA : -$34.38M CL : $12.49B
EBITDA (TTM) TRDA : -$172.23M CL : $3.92B

Return for Risk

TRDA vs. CL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TRDA

TRDA Risk / Return Rank: 33
TRDA Sharpe Ratio Rank: 31
TRDA Sortino Ratio Rank: 39
TRDA Omega Ratio Rank: 42
TRDA Calmar Ratio Rank: 30
TRDA Martin Ratio Rank: 25

CL

CL Risk / Return Rank: 31
CL Sharpe Ratio Rank: 33
CL Sortino Ratio Rank: 27
CL Omega Ratio Rank: 27
CL Calmar Ratio Rank: 33
CL Martin Ratio Rank: 34

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TRDA vs. CL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Entrada Therapeutics, Inc. (TRDA) and Colgate-Palmolive Company (CL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TRDA	CL	Difference
Sharpe ratio: Return per unit of total volatility	-0.24	-0.19	-0.05
Sortino ratio: Return per unit of downside risk	0.35	-0.13	+0.48
Omega ratio: Gain probability vs. loss probability	1.06	0.99	+0.08
Calmar ratio: Return relative to maximum drawdown	-0.31	-0.21	-0.10
Martin ratio: Return relative to average drawdown	-0.83	-0.36	-0.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TRDA vs. CL - Sharpe Ratio Comparison

The current TRDA Sharpe Ratio is -0.24, which is comparable to the CL Sharpe Ratio of -0.19. The chart below compares the historical Sharpe Ratios of TRDA and CL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	TRDA	CL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.24	-0.19	-0.05
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.14	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.21	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.27	0.42	-0.70

Drawdowns

TRDA vs. CL - Drawdown Comparison

The maximum TRDA drawdown since its inception was -85.66%, which is greater than CL's maximum drawdown of -58.91%. Use the drawdown chart below to compare losses from any high point for TRDA and CL.

Drawdown Indicators

	TRDA	CL	Difference
Max Drawdown Largest peak-to-trough decline	-85.66%	-58.91%	-26.75%
Max Drawdown (1Y) Largest decline over 1 year	-64.75%	-18.64%	-46.11%
Max Drawdown (3Y) Largest decline over 3 years	-76.75%	-29.05%	-47.70%
Max Drawdown (5Y) Largest decline over 5 years	—	-29.05%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-29.05%	—
Current Drawdown Current decline from peak	-81.20%	-18.69%	-62.51%
Average Drawdown Average peak-to-trough decline	-62.68%	-11.24%	-51.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	24.30%	11.21%	+13.09%

Volatility

TRDA vs. CL - Volatility Comparison

Entrada Therapeutics, Inc. (TRDA) has a higher volatility of 86.86% compared to Colgate-Palmolive Company (CL) at 6.45%. This indicates that TRDA's price experiences larger fluctuations and is considered to be riskier than CL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TRDA	CL	Difference
Volatility (1M) Calculated over the trailing 1-month period	86.86%	6.45%	+80.41%
Volatility (6M) Calculated over the trailing 6-month period	94.74%	16.66%	+78.08%
Volatility (1Y) Calculated over the trailing 1-year period	84.60%	21.10%	+63.50%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	89.98%	18.64%	+71.34%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	89.98%	19.67%	+70.31%

Dividends

TRDA vs. CL - Dividend Comparison

TRDA has not paid dividends to shareholders, while CL's dividend yield for the trailing twelve months is around 2.46%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CL Colgate-Palmolive Company	2.46%	2.61%	2.18%	2.40%	2.36%	2.10%	2.05%	2.48%	2.79%	2.11%	2.37%	2.25%
TRDA Entrada Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both TRDA and CL in my portfolio?

TRDA and CL have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TRDA or CL?

TRDA has higher volatility (86.86%) compared to CL (6.45%). In terms of maximum drawdown, TRDA dropped -85.66% vs CL's -58.91%.

Which has better risk-adjusted returns?

CL currently has the higher Sharpe Ratio (-0.19 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.